The result of KEGG Classification of target proteinsa.
| Term | Count | Percent% | P value | Genes |
|---|---|---|---|---|
| hsa05200:Pathways in cancer | 11 | 33.33 | 0.00 | AR, CASP3, PPARD, PTGS2, VEGFA, PPARG, PIK3CA, NOS2, IKBKB, FGF2, STAT3 |
| hsa05205:Proteoglycans in cancer | 8 | 24.24 | 0.00 | CASP3, MAPK14, VEGFA, ESR1, PIK3CA, FGF2, STAT3, KDR |
| hsa03320:PPAR signaling pathway | 6 | 18.18 | 0.00 | PPARA, PPARD, SCD, PPARG, FABP4, FABP2 |
| hsa04931:Insulin resistance | 6 | 18.18 | 0.00 | PPARA, PTPRF, PIK3CA, PTPN1, IKBKB, STAT3 |
| hsa04015:Rap1 signaling pathway | 6 | 18.18 | 0.00 | MAPK14, CNR1, VEGFA, PIK3CA, FGF2, KDR |
| hsa04151:PI3K-Akt signaling pathway | 6 | 18.18 | 0.02 | VEGFA, PIK3CA, IKBKB, FGF2, KDR, IL2 |
| hsa04370:VEGF signaling pathway | 5 | 15.15 | 0.00 | PTGS2, MAPK14, VEGFA, PIK3CA, KDR |
| hsa05142:Chagas disease | 5 | 15.15 | 0.00 | MAPK14, PIK3CA, NOS2, IKBKB, IL2 |
| hsa04668:TNF signaling pathway | 5 | 15.15 | 0.00 | CASP3, PTGS2, MAPK14, PIK3CA, IKBKB |
| hsa05145:Toxoplasmosis | 5 | 15.15 | 0.00 | CASP3, MAPK14, NOS2, IKBKB, STAT3 |
| hsa05160:Hepatitis C | 5 | 15.15 | 0.00 | PPARA, MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04014:Ras signaling pathway | 5 | 15.15 | 0.02 | VEGFA, PIK3CA, IKBKB, FGF2, KDR |
| hsa05206:MicroRNAs in cancer | 5 | 15.15 | 0.03 | CASP3, PTGS2, VEGFA, IKBKB, STAT3 |
| hsa05221:Acute myeloid leukemia | 4 | 12.12 | 0.00 | PPARD, PIK3CA, IKBKB, STAT3 |
| hsa05212:Pancreatic cancer | 4 | 12.12 | 0.00 | VEGFA, PIK3CA, IKBKB, STAT3 |
| hsa04917:Prolactin signaling pathway | 4 | 12.12 | 0.00 | MAPK14, ESR1, PIK3CA, STAT3 |
| hsa05222:Small cell lung cancer | 4 | 12.12 | 0.01 | PTGS2, PIK3CA, NOS2, IKBKB |
| hsa04066:HIF-1 signaling pathway | 4 | 12.12 | 0.01 | VEGFA, PIK3CA, NOS2, STAT3 |
| hsa04660:T cell receptor signaling pathway | 4 | 12.12 | 0.01 | MAPK14, PIK3CA, IKBKB, IL2 |
| hsa05169:Epstein-Barr virus infection | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04152:AMPK signaling pathway | 4 | 12.12 | 0.02 | HMGCR, SCD, PPARG, PIK3CA |
| hsa04380:Osteoclast differentiation | 4 | 12.12 | 0.02 | MAPK14, PPARG, PIK3CA, IKBKB |
| hsa04068:FoxO signaling pathway | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, IKBKB, STAT3 |
| hsa04910:Insulin signaling pathway | 4 | 12.12 | 0.02 | PTPRF, PIK3CA, PTPN1, IKBKB |
| hsa04550:Signaling pathways regulating pluripotency of stem cells | 4 | 12.12 | 0.02 | MAPK14, PIK3CA, FGF2, STAT3 |
| hsa05161:Hepatitis B | 4 | 12.12 | 0.02 | CASP3, PIK3CA, IKBKB, STAT3 |
| hsa04932:Non-alcoholic fatty liver disease (NAFLD) | 4 | 12.12 | 0.03 | PPARA, CASP3, PIK3CA, IKBKB |
| hsa05152:Tuberculosis | 4 | 12.12 | 0.04 | VDR, CASP3, MAPK14, NOS2 |
| hsa04923:Regulation of lipolysis in adipocytes | 3 | 9.09 | 0.02 | PTGS2, PIK3CA, FABP4 |
| hsa00140:Steroid hormone biosynthesis | 3 | 9.09 | 0.03 | HSD11B1, HSD11B2, CYP19A1 |
| hsa04210:Apoptosis | 3 | 9.09 | 0.03 | CASP3, PIK3CA, IKBKB |
| hsa05120:Epithelial cell signaling in Helicobacter pylori infection | 3 | 9.09 | 0.03 | CASP3, MAPK14, IKBKB |
| hsa04920:Adipocytokine signaling pathway | 3 | 9.09 | 0.04 | PPARA, IKBKB, STAT3 |
| hsa05140:Leishmaniasis | 3 | 9.09 | 0.04 | PTGS2, MAPK14, NOS2 |
| hsa05133:Pertussis | 3 | 9.09 | 0.04 | CASP3, MAPK14, NOS2 |
a
Bold text means the important pathways reported and involved in diabetes.